Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment. (24th February 2022)

• Record Type: Journal Article
• Authors: Chen, Jin; Gu, Jessie; Shah, Bharti; Stringer, Rowan; Reis da Silva Torrao, Leonel; Hackling, Melissa; Nidamarthy, Prasanna Kumar; Prince, William T.; Woessner, Ralph
• Is Part Of: Journal of clinical pharmacology. Volume 62:Number 4(2022)
• Page Start: 520
• Page End: 531
• Publication Date: 2022-02-24
• Subjects: FXR agonist -- hepatic impairment -- nonalcoholic fatty liver diseases -- pharmacokinetics -- tropifexor; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1996
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Tropifexor, a non–bile acid farnesoid X receptor (FXR) agonist, has dose‐proportional pharmacokinetics and no obvious major enterohepatic circulation. This open‐label study investigated the effect of hepatic impairment (HI), as determined by Child‐Pugh grade, on tropifexor's pharmacokinetics, safety, and tolerability following a 200‐μg dose in the fasted state. Blood samples were collected through 168 hours after dosing for quantification and plasma protein‐binding determination. Total tropifexor exposure was comparable across participants with HI vs those with normal hepatic function. Tropifexor was highly protein bound (>99%) in human plasma across participants of all groups. The average unbound fractions (percentage free) were 0.14% in participants with normal hepatic function and mild HI, which increased to 0.17% and 0.24% in participants with moderate and severe HI, respectively. Similar unbound drug exposure was noted in participants with mild HI and normal hepatic function. Participants with moderate HI (N = 8) had a 1.6‐fold increase in unbound exposure (area under the plasma concentration–time curve from time 0 to infinity [AUCinf, u ]) and a 1.3‐fold increase in maximal exposure (Cmax, u ) vs those with normal hepatic function (geometric mean ratio: AUCinf, u, 1.64 [90%CI, 1.25‐2.16]; Cmax, u, 1.30 [90%CI, 0.96‐1.76]). Participants with severe HI (N = 8) had a 1.6‐fold increase in AUCinf, u (1.61 [90%CI, 1.04‐2.49]) and comparable Cmax, u (1.02 [90%CI, 0.60‐1.72]) compared to participants with normal hepatic function. Tropifexor was well tolerated. The relative insensitivity of tropifexor to HI offers the potential to treat patients with severe liver disease without dose adjustment.